Clinical Trial Update: Durvalumab and Tremelimumab for Pediatric Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating durvalumab and tremelimumab in pediatric malignancies has results posted; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Pediatric Cancer, Solid Tumor Pediatric | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-19